Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
Is Janus Henderson Small/Mid Cap Growth Alpha ETF ( JSMD ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Encompass Health Opens First Connecticut Rehab Hospital in Danbury
EHC opens its first Connecticut rehab hospital in Danbury, boosting its nationwide expansion and meeting rising demand for specialized care.
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
Why Halozyme Therapeutics ( HALO ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.
Powell Warns of Valuation Risks: 5 High Earnings Yield Value Picks
Powell flags lofty valuations, but five high-earnings-yield stocks stand out as value picks in a cautious market.
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience
Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth. Halozyme, Akero, Kiniska, ANI and Twist stand out.
Halozyme Therapeutics and Synopsys have been highlighted as Zacks Bull and Bear of the Day
Halozyme shines with strong growth and partnerships, while Synopsys struggles after earnings miss and lowered outlook.
5 Biotech Stocks Worth Adding to Your Portfolio Now
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector ...
Bull of the Day: Halozyme Therapeutics ( HALO )
The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth ...
Halozyme Therapeutics ( HALO ) Is Up 2.63% in One Week: What You Should Know
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging atai Life Sciences ( ATAI ) This Year?
Here is how atai Life Sciences N.V. (ATAI) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
This Top Medical Stock is a #1 ( Strong Buy ) : Why It Should Be on Your Radar
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Is SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now?
Smart Beta ETF report for ...
5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate Cuts
As Fed rate cuts loom, value investors may eye HALO, PARR, BPOP, PHIN and KT - stocks with high earnings yield and growth potential.
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns
Broker upgrades boost Halozyme, Leidos and TransUnion, each projected for solid 2025 earnings growth and stronger returns.
4 PEG-Rated GARP Stocks That Offer Both Value and Growth
Halozyme, Phibro, Leidos and PDD Holdings stand out as PEG-rated GARP picks, blending value and growth with solid long-term potential.
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics ( HALO ) is a Great Choice
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Best Momentum Stock to Buy for September 3rd
HALO, TROW and CARS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 3, 2025.
Are Medical Stocks Lagging Halozyme Therapeutics ( HALO ) This Year?
Here is how Halozyme Therapeutics (HALO) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.
Halozyme Therapeutics, Inc. ( HALO ) Hit a 52 Week High, Can the Run Continue?
Halozyme Therapeutics (HALO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
New Strong Buy Stocks for September 3rd
TDW, JRVR, HALO, SCSC and CSW have been added to the Zacks Rank #1 (Strong Buy) List on September 3, 2025.
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Here's Why Halozyme Therapeutics ( HALO ) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Janus Henderson Small Cap Growth Alpha ETF ( JSML ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Should Janus Henderson Small Cap Growth Alpha ETF ( JSML ) Be on Your Investing Radar?
Style Box ETF report for ...
Why Halozyme Therapeutics ( HALO ) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
After Golden Cross, Halozyme Therapeutics ( HALO ) 's Technical Outlook is Bright
Is it a good or bad thing when a stock experiences a golden cross technical event?
Here's Why Halozyme Therapeutics ( HALO ) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
What Does the Market Think About Halozyme Therapeutics? - Halozyme Therapeutics ( NASDAQ:HALO )
Halozyme Therapeutics's HALO short percent of float has fallen 5.58% since its last report. The company recently reported that it has 9.60 million shares sold short, which is 10.67% of all regular shares that are available for trading.
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
Halozyme ( HALO ) Q2 EPS Jumps 69%
Halozyme Therapeutics ( NASDAQ:HALO ) , a biotechnology company specializing in drug delivery innovations, released its second-quarter 2025 results on August 5, 2025. The quarter's headline is outperformance: EPS came in at $1.54 ( non-GAAP ) , surpassing the $1.24 non-GAAP consensus and EPS grew ...
Halozyme Therapeutics ( HALO ) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Arcutis Biotherapeutics, Inc. ( ARQT ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Halozyme Therapeutics ( HALO ) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Halozyme Therapeutics ( NASDAQ:HALO )
Halozyme Therapeutics HALO has outperformed the market over the past 15 years by 2.72% on an annualized basis producing an average annual return of 14.99%. Currently, Halozyme Therapeutics has a market capitalization of $7.09 billion.
Why Halozyme Therapeutics ( HALO ) is Poised to Beat Earnings Estimates Again
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Halozyme Therapeutics ( HALO ) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Why Halozyme Therapeutics ( HALO ) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Invesco S&P MidCap 400 GARP ETF ( GRPM ) Be on Your Investing Radar?
Style Box ETF report for ...
Is Invesco S&P MidCap 400 GARP ETF ( GRPM ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years - Halozyme Therapeutics ( NASDAQ:HALO )
Halozyme Therapeutics HALO has outperformed the market over the past 15 years by 2.0% on an annualized basis producing an average annual return of 14.27%. Currently, Halozyme Therapeutics has a market capitalization of $6.64 billion.
